Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Cediranib (Primary) ; Lenalidomide (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 20 Dec 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Sep 2017.
- 07 Jun 2016 Results (n=108) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology